TerraPower commits $450M to build radioisotope production plant.

{
  "signal_id": "2c0f15b3-f388-427c-80f0-6482f1fa8784",
  "signal_type": "news",
  "signal_subtype": "invests_into_assets",
  "detected_at": "2026-03-18T17:14:01+00:00",
  "company": {
    "name": "TerraPower",
    "domain": "terrapower.com"
  },
  "data": {
    "url": "https://www.biospace.com/business/terrapower-commits-450m-to-build-radioisotope-production-plant",
    "title": "TerraPower commits $450M to build radioisotope production plant.",
    "assets": "production facility",
    "excerpt": "TerraPower commits $450M to build radioisotope production plant.\n\nMarch 18, 2026 |\n\nConstructing the cGMP facility will increase availability of actinium-225, a nuclear material central to radiopharmaceutical programs at AstraZeneca, Bristol Myers Squibb, Eli Lilly and Novartis.\n\nTerraPower Isotopes has committed $450 million to build a manufacturing facility in Philadelphia, setting the company up to increase production capacity for a key radioisotope by 20-fold.\n\nThe company, which was co-founded by Bill Gates, is working to increase availability of the alpha-emitting isotope actinium-225. Because actinium-225 emits more energy than lutetium-177, the beta-emitting isotope in Novartis' Lutathera and Pluvicto, companies have identified the nuclear material as an enabler of next-generation radioligand therapies.\n\nRising demand has stretched supply, leading Bristol Myers Squibb's RayzeBio to pause a Phase 3 trial over a shortage of actinium-225 in 2024. The situation has led companies including TerraPower to invest in capacity to make actinium-225.\n\nSuppliers are investing in production to support deals with AstraZeneca, Bayer and other drugmakers that are advancing radioisotope-based cancer therapies.\n\nFebruary 17, 2026\n\nHaving initially served the market from Washington State, TerraPower announced Tuesday that it is establishing a presence on the East Coast by building a...",
    "summary": "TerraPower LLC invested into assets: production facility in Philadelphia, Pennsylvania, United States, Northern America, Americas on Mar 17th '26.",
    "category": "invests_into_assets",
    "found_at": "2026-03-18T17:14:01Z",
    "location": "Philadelphia, Pennsylvania, United States, Northern America, Americas",
    "planning": false,
    "image_url": "https://static.biospace.com/dims4/default/840ab49/2147483647/strip/true/crop/1254x705+0+65/resize/1440x810!/quality/90/?url=https%3A%2F%2Fk1-prod-biospace.s3.us-east-2.amazonaws.com%2Fbrightspot%2F53%2F9d%2F9818d3474d72b4d629af57fcbe0d%2Fistock-1779307150.jpg",
    "confidence": 0.867,
    "assets_tags": [
      "production"
    ],
    "published_at": "2026-03-18T17:14:01Z",
    "location_data": [
      {
        "city": "Philadelphia",
        "state": "Pennsylvania",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-03-17",
    "job_title_tags": [
      "engineering"
    ],
    "article_sentence": "Having initially served the market from Washington State, TerraPower announced Tuesday that it is establishing a presence on the East Coast by building a cGMP-compliant production facility in Philadelphia."
  }
}

curl https://signals.autobound.ai/v1/signals/2c0f15b3-f388-427c-80f0-6482f1fa8784 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"terrapower.com","limit":20}'